Artiva Biotherapeutics, Inc. (ARTV)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
5.91 USD
-0.15
(-2.475%) ⇩
(Oct. 16, 2026, 3:16 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:12 a.m. EDT
The investment case for Artiva Biotherapeutics is currently fractured by a severe disconnect between analyst optimism and market reality. While five analysts rate the stock as a 'strong buy' with a mean target of $35.80—implying a massive upside potential—the actual price action tells a different story. The stock has collapsed approximately 80% over the last year, trading near its 52-week low, which suggests the market has priced in significant risks that analysts may be overlooking or that the consensus is overly optimistic regarding the company's ability to execute. Fundamentally, the business is in distress with negative earnings, negative free cash flow, and a trailing P/E that indicates no profitability. Although the balance sheet appears robust with a current ratio of 24.16 and minimal debt relative to cash, the inability to generate profit or cash flow is a critical flaw for a biotech firm. The recent news of insider purchases provides a glimmer of hope, but it is insufficient to counteract the structural decline in share price. On the short end, the heavy put open interest acts as a magnet, capping any immediate rally. The statistical forecasting model offers virtually no guidance due to extremely low reliability, leaving investors to rely solely on the risky premise that the current low price represents a margin of safety against a potential clinical success. Given the deteriorating price trajectory and lack of earnings, this remains a speculative hold rather than a conviction buy. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.129799 |
| AutoETS | 0.129840 |
| MSTL | 0.130030 |
| AutoARIMA | 0.131989 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 3.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.834 |
| Market Cap | 288,940,608 |
| Forward P/E | -2.27 |
| Beta | 2.41 |
| Website | https://www.artivabio.com |
As of Oct. 10, 2026, 4:12 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at strikes well below the current price. Call activity is sparse and concentrated far out-of-the-money, indicating a lack of immediate bullish conviction despite the company's strong analyst recommendations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.008319497 |
| Address1 | 5,505 Morehouse Drive |
| Address2 | Suite 100 |
| All Time High | 17.31 |
| All Time Low | 1.47 |
| Ask | 14.33 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 462,550 |
| Average Daily Volume3 Month | 401,067 |
| Average Volume | 401,067 |
| Average Volume10Days | 462,550 |
| Beta | 2.413 |
| Bid | 8.05 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 7.122 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.91 |
| Current Ratio | 24.16 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.1 |
| Day Low | 5.82 |
| Debt To Equity | 2.834 |
| Display Name | Artiva Biotherapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -93,462,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.463 |
| Enterprise Value | -43,270,868 |
| Eps Current Year | -2.51 |
| Eps Forward | -2.608 |
| Eps Trailing Twelve Months | -3.23 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.4347 |
| Fifty Day Average Change | -3.5247002 |
| Fifty Day Average Change Percent | -0.373589 |
| Fifty Two Week Change Percent | 0.8319497 |
| Fifty Two Week High | 14.53 |
| Fifty Two Week High Change | -8.62 |
| Fifty Two Week High Change Percent | -0.59325534 |
| Fifty Two Week Low | 2.96 |
| Fifty Two Week Low Change | 2.9499998 |
| Fifty Two Week Low Change Percent | 0.99662155 |
| Fifty Two Week Range | 2.96 - 14.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,721,395,800,000 |
| Float Shares | 19,530,137 |
| Forward Eps | -2.608 |
| Forward P E | -2.2661042 |
| Free Cashflow | -44,431,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 115 |
| Fullday Change | -0.1500001 |
| Fullday Change Percent | -2.475249 |
| Fullday Price | 5.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15096 |
| Held Percent Institutions | 0.84248 |
| Implied Shares Outstanding | 48,890,121 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-07-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California. |
| Long Name | Artiva Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 288,940,608 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_672643147 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -90,821,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 376,942,832 |
| Number Of Analyst Opinions | 5 |
| Open | 6.08 |
| Operating Cashflow | -75,232,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Phone | 858 267 4467 |
| Previous Close | 6.06 |
| Price Eps Current Year | -2.3545816 |
| Price Hint | 2 |
| Price To Book | 0.829823 |
| Profit Margins | 0.0 |
| Quick Ratio | 24.061 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.1500001 |
| Regular Market Change Percent | -2.475249 |
| Regular Market Day High | 6.1 |
| Regular Market Day Low | 5.82 |
| Regular Market Day Range | 5.82 - 6.1 |
| Regular Market Open | 6.08 |
| Regular Market Previous Close | 6.06 |
| Regular Market Price | 5.91 |
| Regular Market Time | 1,792,178,198 |
| Regular Market Volume | 457,176 |
| Return On Assets | -0.22338 |
| Return On Equity | -0.36581 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 48,890,121 |
| Shares Percent Shares Out | 0.047 |
| Shares Short | 2,296,734 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,836,137 |
| Short Name | Artiva Biotherapeutics, Inc. |
| Short Percent Of Float | 0.0926 |
| Short Ratio | 4.88 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARTV |
| Target High Price | 41.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 35.8 |
| Target Median Price | 40.0 |
| Total Cash | 349,393,984 |
| Total Cash Per Share | 7.147 |
| Total Debt | 9,849,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.97205 |
| Two Hundred Day Average Change | -2.0620503 |
| Two Hundred Day Average Change Percent | -0.25866 |
| Type Disp | Equity |
| Volume | 457,176 |
| Website | https://www.artivabio.com |
| Zip | 92,121 |